GV 101
Alternative Names: GV-101; OV-888Latest Information Update: 05 Jul 2024
At a glance
- Originator Graviton
- Developer Graviton; Ovid Therapeutics
- Class Antifibrotics; Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cavernous haemangioma
- Clinical Phase Unknown CNS disorders
- Preclinical Hepatic fibrosis
Most Recent Events
- 01 Jul 2024 Pharmacokinetics, Pharmacodynamics and adverse events data from a phase I trial in Cavernous haemangiona released by Ovid Therapeutics
- 14 May 2024 Ovid Therapeutics completes a phase-I MAD trial in Cavernous haemangioma (PO)
- 13 May 2024 Clinical trials in CNS disorders (PO) before May 2024 (Ovid Therapeutics pipeline, May 2024)